From the Department of Dermatology, the First Affiliated Hospital of Nanjing Medical University , Nanjing, Jiangsu , China.
J Dermatolog Treat. 2012 Dec;23(6):449-52. doi: 10.3109/09546634.2011.579082. Epub 2011 Jul 31.
As the most frequently used systemic antifungal agents for onychomycosis, terbinafine and itraconazole have both proved to have the conditions of recurrence in various degrees during follow-up period after end of therapy; very little is known about their comparative recurrences after long-term follow-up. We conducted a meta-analysis of available trials to compare the long-term recurrences of toenail onychomycosis after successful treatment with terbinafine versus itraconazole. Meta-analysis was performed by the Review Manager version 5.0.25. Risk ratio and 95% confidence intervals were calculated by the fixed effect model. Five trials and total 251 eligible patients were included in this meta-analysis. The combined risk ratio of the meta-analysis comparing terbinafine with itraconazole for mycological recurrence rate was 0.44 (95% CI 0.29-0.66), which suggests that itraconazole therapy is more likely to produce mycological recurrence compared with terbinafine therapy.
作为最常用于治疗甲真菌病的全身性抗真菌药物，特比萘芬和伊曲康唑在治疗结束后的随访期内均已证明存在不同程度的复发情况；但对于它们在长期随访后的复发情况却知之甚少。我们对现有试验进行了荟萃分析，以比较特比萘芬与伊曲康唑治疗成功后的甲真菌病长期复发情况。荟萃分析采用 Review Manager 版本 5.0.25 进行。采用固定效应模型计算风险比和 95%置信区间。本荟萃分析共纳入了 5 项试验，总计 251 名合格患者。比较特比萘芬与伊曲康唑的真菌学复发率的荟萃分析的合并风险比为 0.44（95%CI 0.29-0.66），这表明与特比萘芬治疗相比，伊曲康唑治疗更有可能导致真菌学复发。
